Navya Pillikunte Doddareddy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Navya Pillikunte Doddareddy has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Mihirkumar P. Parmar
Gujarat Medical Education and Research Society
2 shared publications Vishal Venugopal
Bhaarath Medical College and Hospital, Chennai, India
2 shared publications- Babu Vishva
Department of Pathology, JIPMER, Pondicherry, India
1 shared publication - Berjis Rahmath
Osmania Medical College, Hyderabad, Telangana, India
1 shared publication - Lyluma Ishfaq
Government medical college, Srinagar, Directorate of health services Kashmir Srinagar, J&k , India
1 shared publication - Mudit Moondra
RNT Medical College, Udaipur, India
1 shared publication
Latest Publications
- Open Access
- 22 September 2023
- Published by Springer Nature in Research Square
A Systematic Review on NSAID and Tanezumab efficacy in Chronic Lower Back Pain
Chronic back pain is an ailment that impacts people of all ages and lasts longer than 12 weeks. 7.41% of all Years Lost to Disability (YLD) are associated with low back pain, which makes it the pathology responsible for the most YLD, surpassing other chronic conditions such as Diabetes and Depression. Despite the prevalence of drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), painkillers, and biologics, the types of drugs administered to individuals differ greatly. We collected data from the PubMed database of the PubMed database, National Library of Medicine (NIH), and Google Scholar. Randomized controlled trials (RCTs) that explicitly evaluate the effectiveness of various NSAIDs in adult patients with chronic back pain were selected for this study. After an exhaustive search and examination of numerous publications, only 8 articles met the inclusion criteria. In recent studies that included NSAIDs, they were among the most frequently prescribed medications for the treatment of chronic low back pain. In comparison to placebo, selective COX-II inhibitors such as celecoxib and etoricoxib were found to be efficacious, while valdecoxib was associated with serious side effects. In addition to reducing back pain, COX-II inhibitors with a preference for COX-II, such as aceclofenac and diclofenac, were associated with gastrointestinal side effects. Despite the risk of joint degeneration and accelerated osteoarthritis, intravenous tanezumab may be superior to naproxen and placebo in treating chronic low back pain.
- 22 September 2023
- Published by Springer Nature in Research Square
Open AccessA Systematic Review on NSAID and Tanezumab efficacy in Chronic Lower Back Pain
Chronic back pain is an ailment that impacts people of all ages and lasts longer than 12 weeks. 7.41% of all Years Lost to Disability (YLD) are associated with low back pain, which makes it the pathology responsible for the most YLD, surpassing other chronic conditions such as Diabetes and Depression. Despite the prevalence of drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), painkillers, and biologics, the types of drugs administered to individuals differ greatly. We collected data from the PubMed database of the PubMed database, National Library of Medicine (NIH), and Google Scholar. Randomized controlled trials (RCTs) that explicitly evaluate the effectiveness of various NSAIDs in adult patients with chronic back pain were selected for this study. After an exhaustive search and examination of numerous publications, only 8 articles met the inclusion criteria. In recent studies that included NSAIDs, they were among the most frequently prescribed medications for the treatment of chronic low back pain. In comparison to placebo, selective COX-II inhibitors such as celecoxib and etoricoxib were found to be efficacious, while valdecoxib was associated with serious side effects. In addition to reducing back pain, COX-II inhibitors with a preference for COX-II, such as aceclofenac and diclofenac, were associated with gastrointestinal side effects. Despite the risk of joint degeneration and accelerated osteoarthritis, intravenous tanezumab may be superior to naproxen and placebo in treating chronic low back pain.
- Open Access
- 19 September 2023
- Published by Springer Nature in Research Square
Genetic Variants Affecting Insulin Signaling Pathways and Risk of Diabetes: A Comprehensive Systematic Review
Purpose The complicated condition known as type 2 diabetes mellitus (T2DM) has a diverse genetic and environment-related cause. MIM125853 is among the heterogeneous diseases that can also be characterized as a multifactorial disorder of glucose metabolism with genetic susceptibility of an anomaly in the insulin pathway. We conducted the review with aim to assess the genetic variants affecting the insulin pathway as well as evaluate the risk of diabetes in association with genetic variants. Methods We used literature of 13 researches that met the inclusion criteria after the process of selection and analyzation. Our analysis included 59,593 participants in total with a gender distribution of 48% males (n = 24,591) and 52% females (n = 35,002). Result Gene variants such as PPARG, SLC30A8, KCNJ11, TCF7L2 and many others plays a pivotal role in the development of type-II diabetes as well as optimal functioning of insulin metabolic pathway for glucose metabolism and distribution with circulation. Conclusion KCNJ11 regulates insulin release in collaboration with other genes including ABCC8, KAPN10, IRS1 and TCF7L2. Reduced mutual expression of these kinds of genes could contribute to DM susceptibility. However, it is still unknown how precisely the combination of these genes’ functions in the control of insulin secretion.
- 19 September 2023
- Published by Springer Nature in Research Square
Open AccessGenetic Variants Affecting Insulin Signaling Pathways and Risk of Diabetes: A Comprehensive Systematic Review
Purpose The complicated condition known as type 2 diabetes mellitus (T2DM) has a diverse genetic and environment-related cause. MIM125853 is among the heterogeneous diseases that can also be characterized as a multifactorial disorder of glucose metabolism with genetic susceptibility of an anomaly in the insulin pathway. We conducted the review with aim to assess the genetic variants affecting the insulin pathway as well as evaluate the risk of diabetes in association with genetic variants. Methods We used literature of 13 researches that met the inclusion criteria after the process of selection and analyzation. Our analysis included 59,593 participants in total with a gender distribution of 48% males (n = 24,591) and 52% females (n = 35,002). Result Gene variants such as PPARG, SLC30A8, KCNJ11, TCF7L2 and many others plays a pivotal role in the development of type-II diabetes as well as optimal functioning of insulin metabolic pathway for glucose metabolism and distribution with circulation. Conclusion KCNJ11 regulates insulin release in collaboration with other genes including ABCC8, KAPN10, IRS1 and TCF7L2. Reduced mutual expression of these kinds of genes could contribute to DM susceptibility. However, it is still unknown how precisely the combination of these genes’ functions in the control of insulin secretion.